Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00238615 · ClinicalTrials.gov registry record · Phase 2
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00238615: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00238615 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00238615, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to assess how well this particular combination of chemotherapy, radiation and surgery works to help people with locally advanced lung cancer, how well PET scans indicates whether someone has responded to chemotherapy and radiation, and gene expression patterns related to outcomes in patients with locally advanced lung cancer who receive this treatment regimen.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- PROCEDURE Surgical resection
- PROCEDURE Radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2003-03 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00238615
The ClinicalTrials.gov registry entry for NCT00238615 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00238615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00238615 about?
NCT00238615 is a clinical study titled "Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC". The purpose of this study is to assess how well this particular combination of chemotherapy, radiation and surgery works to help people with locally advanced lung cancer, how well PET scans indicates whether someone has responded to chemotherapy and radiation, and gene expression patterns related to...
What is the current status of trial NCT00238615?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2003-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00238615?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Surgical resection (PROCEDURE), Radiation therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00238615?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.